glp-1 class diabetes drugs What to Make of the Coverage and Cost Landscape Thinking about a GLP-1 medication?
Description
The rise in insulin with the decrease in glucagon was associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal
Neuroscience Letters
[60] History and clinical trials [edit] In the 1970s, Jens Juul Holst and Joel Habener began research on GLP-1, initially in relation to duodenal ulcer disease
One such substance, LY3437943, has been discovered to exhibit strong agonist activity on three distinct receptors, including the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors
